<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373462</url>
  </required_header>
  <id_info>
    <org_study_id>4-2014-0888</org_study_id>
    <nct_id>NCT02373462</nct_id>
  </id_info>
  <brief_title>Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of olmesartan on walking distance and quality of life in peripheral
      artery disease patients with hypertension treated For intermittent claudication.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The data of the paper referenced in the preparation of the protocols in this task were
    manipulated and the paper was withdrawn.
  </why_stopped>
  <start_date type="Actual">August 25, 2015</start_date>
  <completion_date type="Actual">November 17, 2015</completion_date>
  <primary_completion_date type="Actual">November 17, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain free maximum walking distance and time</measure>
    <time_frame>12th week</time_frame>
    <description>Effect of olmesartan in maximum, pain free walking distance &amp; time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by questionnaires</measure>
    <time_frame>24th week</time_frame>
    <description>Effect of olmesartan in quality of life (WIQ, SF-36)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pulse wave analysis as measured by PWV</measure>
    <time_frame>24th week</time_frame>
    <description>pulse wave velocity</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure by measured by 24hr ABPM</measure>
    <time_frame>24th week</time_frame>
    <description>24hr ambulatory blood pressure monitoring</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Peripheral Artery Disease With Intermittent Claudication</condition>
  <arm_group>
    <arm_group_label>olmesartan group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olmesartan (20mg qd then 40mg qd for titrating BP &lt;140/90 mmHg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>other group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>other anti-hypertensive drug (titrating BP &lt;140/90 mmHg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan</intervention_name>
    <arm_group_label>olmesartan group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>other anti-hypertensive drug</intervention_name>
    <description>CCB, diuretics, alpha blocker, direct vasodilator, beta blocker</description>
    <arm_group_label>other group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 20 and 85 years at visit 1

          -  Patients with ankle-brachial index (ABI) of less than 0.9 in one or both legs with
             history of intermittent claudication stable for the previous 6 months

          -  Patients whose statins, anti hypertensive medications and antiplatelet medications are
             stable for the past 6 months. Statins and cilostazol are allowed but needs to be
             stable for the past 6 months (diabetic medications may be changed)

          -  Patients whose blood pressure is more than 140/90 mmHg with/without anti-hypertension
             treatment

        Exclusion Criteria:

          -  Blood pressure of more than 180/110 mmHg

          -  Patients taking ARBs or ACE inhibitors treatment for at least 6 months before

          -  Patients taking aldosterone receptor antagonists at least 6 months before

          -  Patients with serum creatinine of more than 3 mg/dL

          -  serum potassium (K+) &gt; 5.5mg/dl

          -  History of bilateral renal artery stenosis

          -  History of acute coronary syndrome or heart failure hospitalization within 6 months

          -  Peripheral arterial revascularization planned within 1 month

          -  Critical limb ischemia

          -  Patients with impaired cognition (e.g. dementia)

          -  pregnancy or women at age of childbearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 14, 2015</study_first_submitted>
  <study_first_submitted_qc>February 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <last_update_submitted>January 24, 2019</last_update_submitted>
  <last_update_submitted_qc>January 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

